95 related articles for article (PubMed ID: 24440159)
1. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series.
Harper DM; Verdenius I; Harris GD; Barnett AL; Rosemergey BE; Arey AM; Wall J; Malnar GJ
Prev Med; 2014 Apr; 61():20-5. PubMed ID: 24440159
[TBL] [Abstract][Full Text] [Related]
2. Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest.
Verdenius I; Harper DM; Harris GD; Griffith RS; Wall J; Hempstead LK; Malnar GJ; Bekkers RL
PLoS One; 2013; 8(8):e71295. PubMed ID: 23951123
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting completion of the human papillomavirus vaccine series.
Gold R; Naleway A; Riedlinger K
J Adolesc Health; 2013 Apr; 52(4):427-32. PubMed ID: 23298984
[TBL] [Abstract][Full Text] [Related]
4. Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates.
Sandri KJ; Verdenius I; Bartley MJ; Else BM; Paynter CA; Rosemergey BE; Harris GD; Malnar GJ; Harper SM; Griffith RS; Bonham AJ; Harper DM
PLoS One; 2014; 9(5):e96277. PubMed ID: 24816199
[TBL] [Abstract][Full Text] [Related]
5. Quantifying clinical HPV4 dose inefficiencies in a safety net population.
Harper DM; Verdenius I; Ratnaraj F; Arey AM; Rosemergey B; Malnar GJ; Wall J
PLoS One; 2013; 8(11):e77961. PubMed ID: 24223131
[TBL] [Abstract][Full Text] [Related]
6. Safety of quadrivalent human papillomavirus vaccine administered routinely to females.
Klein NP; Hansen J; Chao C; Velicer C; Emery M; Slezak J; Lewis N; Deosaransingh K; Sy L; Ackerson B; Cheetham TC; Liaw KL; Takhar H; Jacobsen SJ
Arch Pediatr Adolesc Med; 2012 Dec; 166(12):1140-8. PubMed ID: 23027469
[TBL] [Abstract][Full Text] [Related]
7. A randomized intervention of reminder letter for human papillomavirus vaccine series completion.
Chao C; Preciado M; Slezak J; Xu L
J Adolesc Health; 2015 Jan; 56(1):85-90. PubMed ID: 25438965
[TBL] [Abstract][Full Text] [Related]
8. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals.
Russell K; Dunne EF; Kemper AR; Dolor RJ; Unger ER; Panicker G; Markowitz LE; Walter EB
Vaccine; 2015 Apr; 33(16):1953-8. PubMed ID: 25744229
[TBL] [Abstract][Full Text] [Related]
10. Philanthropic support of HPV vaccination efforts.
McCandless B; Sharpe BR
Prev Med; 2015 Jul; 76():126. PubMed ID: 25657169
[No Abstract] [Full Text] [Related]
11. In a safety net population HPV4 vaccine adherence worsens as BMI increases.
Harper DM; Else BM; Bartley MJ; Arey AM; Barnett AL; Rosemergey BE; Paynter CA; Verdenius I; Harper SM; Harris GD; Groner JA; Malnar GJ; Wall J; Bonham AJ
PLoS One; 2014; 9(7):e103172. PubMed ID: 25076128
[TBL] [Abstract][Full Text] [Related]
12. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011.
Schmidt MA; Gold R; Kurosky SK; Daley MF; Irving SA; Gee J; Naleway AL
J Adolesc Health; 2013 Nov; 53(5):637-41. PubMed ID: 24138765
[TBL] [Abstract][Full Text] [Related]
13. Long-term study of a quadrivalent human papillomavirus vaccine.
Ferris D; Samakoses R; Block SL; Lazcano-Ponce E; Restrepo JA; Reisinger KS; Mehlsen J; Chatterjee A; Iversen OE; Sings HL; Shou Q; Sausser TA; Saah A
Pediatrics; 2014 Sep; 134(3):e657-65. PubMed ID: 25136050
[TBL] [Abstract][Full Text] [Related]
14. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with completion of the human papillomavirus vaccine series.
Neubrand TP; Breitkopf CR; Rupp R; Breitkopf D; Rosenthal SL
Clin Pediatr (Phila); 2009 Nov; 48(9):966-9. PubMed ID: 19483128
[No Abstract] [Full Text] [Related]
16. Response to philanthropic support of HPV vaccination efforts.
Harper DM; Wall J; Verdenius I; Harris GD
Prev Med; 2015 Jul; 76():127-8. PubMed ID: 25657170
[No Abstract] [Full Text] [Related]
17. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.
Geier DA; Geier MR
Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with human papillomavirus vaccination completion on a catch-up schedule.
Perry R; Rankin K; Yu MC; Harwood B
Obstet Gynecol; 2014 Jul; 124(1):76-81. PubMed ID: 24901268
[TBL] [Abstract][Full Text] [Related]
19. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
[TBL] [Abstract][Full Text] [Related]
20. Acceptance and compliance with postpartum human papillomavirus vaccination.
Wright JD; Govindappagari S; Pawar N; Cleary K; Burke WM; Devine PC; Lu YS; Tsai WY; Lewin SN; Herzog TJ
Obstet Gynecol; 2012 Oct; 120(4):771-82. PubMed ID: 22996094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
